Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its ImplicationsMin Zhu, Sameer Doshi, Jessica Johnson et al.|Clinical Pharmacokinetics|2016Cited by 213
Blinatumomab Pharmacodynamics and Exposure–Response Relationships in Relapsed/Refractory Acute Lymphoblastic LeukemiaMin Zhu, Sameer Doshi, Andrea Kratzer et al.|The Journal of Clinical Pharmacology|2017Cited by 34
Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).Min Zhu, Sameer Doshi, Andreas Wolf et al.|Journal of Clinical Oncology|2015Cited by 7